# A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

> **NCT06186622** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 50 (actual)

## Conditions studied

- Healthy
- Obese
- Overweight

## Interventions

- **DRUG:** Orforglipron
- **DRUG:** Simvastatin
- **DRUG:** Digoxin
- **DRUG:** Rosuvastatin
- **DRUG:** Acetaminophen
- **DRUG:** Midazolam
- **DRUG:** Sodium Bicarbonate

## Key facts

- **NCT ID:** NCT06186622
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-02
- **Primary completion:** 2024-07-10
- **Final completion:** 2024-07-10
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06186622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06186622, "A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06186622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*